Drug Profile
Research programme: antimetastatic therapeutics - Supratek
Alternative Names: SP-MET-1; SP-MET-2; SP-MET-X1; SP-MET-X2Latest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Supratek Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Feb 2023 Discontinued - Preclinical for Cancer in Canada (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 28 Nov 2007 Preclinical development is ongoing